P/B
17
SELLAS Life Sciences Group
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
$2.3B
Market Cap • 9/25/2026
2006
(20 years)
Founded
2008
(18 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
—
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
0,9
EPS
—
Market Cap
Market Cap
2,3B
EV
2,2B
EV/Revenue
0
EV/EBITDA
-62,7
EV/EBIT
-62,7
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-6%
Total Yield
-6%
Dividend Yield 5Y
0%
Payout
0%
Retained Earnings
-293M
Profitability
Gross Margin
—
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
0%
Capex/Revenue
0%
Capex/D&A
0%
Capex/OCF
0%
SBC/OCF
—
% PPE
0,5%
% Goodwill
1,3%
ROE
—
ROIC
—
Growth
CAGR Revenue 5Y
-100%
CAGR Op. Income 5Y
18,1%
CAGR Net Income 5Y
16,4%
CAGR EPS 5Y
-30,2%
CAGR OCF 5Y
13,1%
Leverage
N.D./EBITDA
3,9
Debt/Equity
0%
Current Ratio
18,8
Quick Ratio
18,3
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!